Identification of T-cell epitopes for cancer immunotherapy.
about
T-cell receptor gene therapy--ready to go viral?Multidrug-resistance proteins are weak tumor associated antigens for colorectal carcinoma.Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations.A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens.Strategies for cancer vaccine development.Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients.Potential target antigens for a universal vaccine in epithelial ovarian cancer.Applications for T-cell epitope queries and tools in the Immune Epitope Database and Analysis Resource.Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of conceptStrategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantationIdentification of human leukemia antigen A*0201-restricted epitopes derived from epidermal growth factor pathway substrate number 8Identification of HLA-A*11:01-restricted Mycobacterium tuberculosis CD8(+) T cell epitopes.Inducible T-cell receptor expression in precursor T cells for leukemia control.Identification and translational validation of novel mammaglobin-A CD8 T cell epitopesEffective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunityTargeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine.Discovery of immunodominant T-cell epitopes reveals penton protein as a second immunodominant target in human adenovirus infection.Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development.Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes.HLA class I molecules reflect an altered host proteome after influenza virus infection.Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens.Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD).Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge.Systems vaccinology for cancer vaccine development.Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia.Prospect and progress of personalized peptide vaccinations for advanced cancers.The immunogenicity of a novel cytotoxic T lymphocyte epitope from tumor antigen PL2L60 could be enhanced by 4-chlorophenylalanine substitution at position 1.Characterization of Ewing sarcoma associated cancer/testis antigensHSPVdb--the Human Short Peptide Variation Database for improved mass spectrometry-based detection of polymorphic HLA-ligands.High expression of the evolutionarily conserved alpha/beta hydrolase domain containing 6 (ABHD6) in Ewing tumors.Therapeutic Antibodies against Intracellular Tumor AntigensIdentification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myelomaIdentification of native, immunogenic peptides from Cyclin D1.Computational study on the origin of the cancer immunotherapeutic potential of B and T cell epitope peptides.Effects of poly(I:C) and MF59 co-adjuvants on immunogenicity and efficacy of survivin polypeptide immunogen against melanoma.
P2860
Q28081611-69BDD19C-2998-400F-9629-FAEC5849BC55Q31022597-A7501492-2D65-48FC-BE0A-BA23C911BE00Q33992114-CEC45F6D-F3E3-404A-9066-86C1A967F150Q33995557-DB831E76-B857-4B41-A550-1DCD14A1A0D6Q34004266-9D0268A7-219A-4D13-B5D5-FE54E64FEAACQ34038338-6A293B55-D8B0-4C2A-8975-B284EDF3881EQ34093600-A63ADD62-07DE-4B5F-8A21-9958C6838C5AQ34159451-C38BA6FB-78A9-497E-884C-F3232BA2142EQ34586710-9896D8E2-0B9B-427E-AF0F-0FAC14521BFBQ34898280-F3C7CAA7-EB0C-4B2B-9111-BD1AE6F7C245Q35193892-BC2F2921-6056-4587-8DD0-D0A9C8624D96Q35588845-85A55E7E-C81D-4CB6-B7DD-51490CF3D7F4Q35724710-498ABE23-B7B6-43F6-BC7B-5034D8A32F44Q35987898-BCEDF35D-B47B-4104-A19A-160E56695D54Q36166038-5B7ADE93-288B-4D48-B244-6D214223050FQ36623597-6FE03317-9CCC-4AFA-A83B-11CF6E14410DQ36693023-0AD9F2D9-C71E-482C-9E25-B46B2A186539Q37259608-B384367F-29C0-4B10-84AD-F93398AAE16DQ37322142-4B58F18B-FFBD-400B-903E-C5A9384939BEQ37334596-746788D5-DC51-4D95-A1A7-6E7F5C5504ACQ37456000-00F11A95-A220-4D4E-9571-3BD663F2B8C4Q37475195-0D617913-9752-497D-80D5-02CBE0818887Q37480760-3C8CC110-4FCF-4921-85AD-3B6CFC46FD91Q37636670-221A2A83-9591-4EA0-AD4F-0A2775211FC1Q37659113-D5654D6D-6727-44ED-9823-68EF8D336F91Q37674253-2C4AB89D-D184-45BC-84F1-270D9113D9DAQ37952805-1C8B9F3C-9928-418F-8DD9-6EA0076C86ECQ38091088-0ED0FA3E-5B50-4D0B-ACE6-EB4EC171B76BQ38207141-6D100B90-89AA-4F4F-8256-C32370F1A54BQ38752567-75A64E6E-65BF-4A61-8762-F586D89730FDQ38758988-36FE18D7-FEDE-4321-A5D4-38AB013672C8Q39090059-897B6412-798D-4510-A9C7-DCE3EA508468Q39215865-103A9B65-AE70-4B6C-B692-A23B6B2179C9Q39624857-7E0FB7DC-62E9-457B-AB76-C6C0CE747171Q39793314-381FD9FC-6A63-4F2A-988E-870E6DCA37D6Q41462883-78F2D9CA-5EB4-4C4F-8B90-1972A8E623A5Q42287234-7958C16E-5AB6-4C7B-9BFC-B52279BA3A58Q44399322-70C885FA-C63F-4AA6-8D97-243FB60ADD52Q45945817-87D029B3-B894-4365-A6D1-8EC2653F0410Q47282640-436EF5A2-51CA-4839-A202-8138E94E95FB
P2860
Identification of T-cell epitopes for cancer immunotherapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Identification of T-cell epitopes for cancer immunotherapy.
@en
type
label
Identification of T-cell epitopes for cancer immunotherapy.
@en
prefLabel
Identification of T-cell epitopes for cancer immunotherapy.
@en
P2860
P356
P1433
P1476
Identification of T-cell epitopes for cancer immunotherapy.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404787
P577
2007-07-05T00:00:00Z